Filing Details
- Accession Number:
- 0001127602-16-051285
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-05-05 20:16:28
- Reporting Period:
- 2016-05-03
- Filing Date:
- 2016-05-05
- Accepted Time:
- 2016-05-05 20:16:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 318154 | Amgen Inc | AMGN | Biological Products, (No Disgnostic Substances) (2836) | 953540776 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1555508 | Madhavan Balachandran | One Amgen Center Drive Thousand Oaks CA 91320-1799 | Evp, Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2016-05-04 | 30,000 | $154.12 | 55,996 | No | 4 | S | Indirect | By Family Trust |
| Common Stock | Acquisiton | 2016-05-03 | 3,581 | $0.00 | 23,097 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By Family Trust |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Nqso (Right to Buy) | Acquisiton | 2016-05-03 | 30,490 | $0.00 | 30,490 | $156.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,490 | 2018-05-03 | 2026-05-03 | No | 4 | A | Direct |
Footnotes
- The price reported is an average price. The prices ranged from $153.53 to $154.54 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.
- The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
- These shares include the following RSUs granted under the Company's equity plans: 9,056 RSUs which vest in one installment on 7/31/2016; 2,543 RSUs which vest on 1/28/2017; 3,154 RSUs which vest in one installment of 1,553 on 1/31/2017 and one installment of 1,601 on 1/31/2018; 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019; and 3,581 RSUs which vest in installments of 1,181 on 5/3/2018, 1,182 on 5/3/2019 and 1,218 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- These shares include 1,086 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
Billionaire Hedge Funds
